# Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial

> **NCT03318783** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 20 (actual)

## Conditions studied

- Subarachnoid Hemorrhage, Aneurysmal
- Delayed Cerebral Ischemia
- Vasospasm, Cerebral
- Endothelial Dysfunction

## Interventions

- **DRUG:** GSK2256294
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03318783
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2019-04-03
- **Final completion:** 2020-01-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318783, "Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03318783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*